Background And Purpose: The correlates of motor parkinsonism in Alzheimer's disease (AD) remain controversial. The effects of nigrostriatal dopaminergic degeneration on parkinsonism and cognition in biomarker-validated patients with AD were evaluated.

Methods: This study recruited 116 patients with AD who underwent dual-phase F-N-(3-fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane positron emission tomography, F-florbetaben positron emission tomography, 3 T brain magnetic resonance imaging, and Unified Parkinson's Disease Rating Scale (UPDRS) and neuropsychological tests. The mean cortical thickness in the frontal, temporal, parietal and occipital cortices, and the dopamine transporter (DAT) uptake in the caudate, anterior/posterior putamen and substantia nigra were quantified. The relationship between DAT uptake, mean lobar cortical thickness, UPDRS motor score and cognition was investigated using general linear models (GLMs) after controlling for age, sex, education, intracranial volume, and deep and periventricular white matter hyperintensities. A path analysis was performed for the UPDRS motor score with the same covariates.

Results: Path analysis and multivariable GLMs for UPDRS motor score showed that lower caudate DAT uptake was directly associated with a higher UPDRS motor score, whereas caudate DAT uptake confounded the association between mean frontal/parietal thickness and UPDRS motor score. Multivariable GLMs for cognitive scores showed that lower caudate DAT uptake was associated with visuospatial/executive dysfunction independent of mean frontal or parietal thickness.

Conclusions: Nigrostriatal dopaminergic dysfunction is associated with parkinsonism and visuospatial/executive dysfunction in patients with AD.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.15995DOI Listing

Publication Analysis

Top Keywords

dat uptake
20
updrs motor
20
motor score
20
caudate dat
12
dopamine transporter
8
parkinsonism cognition
8
alzheimer's disease
8
nigrostriatal dopaminergic
8
positron emission
8
emission tomography
8

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Yonsei University College of Medicine, Seoul, Korea, Republic of (South).

Background: To investigate the relationship between basal forebrain (BF) cholinergic activity, dopaminergic degeneration, white matter hyperintensities (WMHs), and their effects on clinical manifestations of Alzheimer's disease (AD) and Lewy body disease (LBD).

Method: A total of 407 subjects who underwent 3-T MRI, dopamine transporter (DAT) positron emission tomography, neuropsychological tests, and assessments for parkinsonism, cognitive fluctuation (CF), visual hallucination (VH), and rapid eye movement sleep behavior disorder (RBD) were evaluated for probable AD, LBD, or both (AD+LBD). General linear models were used to investigate the relationships between BF volume (BFV), striatal DAT uptake, WMHs, and clinical manifestations after controlling for age, sex, education, vascular factors, and intracranial volume.

View Article and Find Full Text PDF

Technology and Dementia Preconference.

Alzheimers Dement

December 2024

Research Program on Cognition and Neuromodulation-Based Interventions, University of Michigan, Ann Arbor, MI, USA.

Background: The computerized NIH Toolbox Cognition Battery (NIHTB-CB) was designed to assess cognitive functioning across the lifespan. Previous studies demonstrated that NIHTB-CB measures discriminate between healthy controls (HCs), individuals with amnestic mild cognitive impairment (aMCI), and individuals with dementia of the Alzheimer's type (DAT). Scores on NIHTB-CB tasks also correspond with performance on well-validated neuropsychological measures of the same cognitive domains.

View Article and Find Full Text PDF

Background: Longitudinal cognitive changes in Parkinson's disease (PD) exhibit considerable heterogeneity.Predicting cognitive trajectories in early PD patients can improve prognostic counseling and guide clinical trials.

Methods: This study included 337 early PD patients with 6-year follow-up in the Parkinson's Progression Markers Initiative (PPMI) database.

View Article and Find Full Text PDF

Cerebrospinal fluid tau and disease progression in early Parkinson's disease: an 8-year longitudinal study.

J Neurol

December 2024

Department of Neurology, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, Sichuan, 610041, China.

Objective: To explore whether CSF phosphorylated tau-181 (P-tau181) and total tau (T-tau) are associated with disease progression in early PD patients.

Methods: We analyzed 8-year longitudinal clinical data from 368 early, drug-naive PD patients and 185 matched controls from the Parkinson's Progression Markers Initiative cohort. CSF P-tau181 and T-tau were measured over 5 years, while CSF α-synuclein was measured over 3 years.

View Article and Find Full Text PDF

Objective: Although basal forebrain (BF) cholinergic degeneration and white matter hyperintensities (WMHs) are important in neurodegeneration in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), their relationships with dopaminergic degeneration and clinical manifestations remain unclear.

Methods: A total of 407 patients with cognitive impairment meeting the diagnostic criteria for AD, DLB, or both (AD+DLB) were assessed. All participants underwent 3T MRI, dopamine transporter (DAT) positron emission tomography, neuropsychological tests, and assessments for parkinsonism, cognitive fluctuation, visual hallucination, and rapid eye movement sleep behavior disorder (RBD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!